Luveniq panel canceled

FDA canceled the Dermatologic and Ophthalmic Drugs Advisory Committee meeting that was scheduled for June 28 to discuss an NDA from Lux Biosciences Inc. (Jersey City, N.J.) for Luveniq voclosporin. The agency said the meeting was canceled to allow time for the resolution of "several outstanding issues." Lux declined to comment on the cancellation, but said it continues to expect a decision by the PDUFA date of Aug. 3. The application is under Priority Review to treat non-infectious uveitis in the intermediate or posterior segments of the eye. ...